GLP-1 Drugs Explored for Addiction Treatment in New Clinical Trial
A $13 million study will investigate if medications like Ozempic can reduce cravings for alcohol and opioids, potentially impacting crime, homelessness, and child welfare.
A new $13 million randomized controlled trial aims to determine if GLP-1 drugs, known for treating diabetes and aiding weight loss, can also help curb cravings for alcohol and opioids. The study, supported by the Arnold Foundation, is a collaboration between the Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services.
The trial will test whether weekly injections of Ozempic or Wegovy, in addition to standard care, can reduce alcohol and opioid use. Researchers will also assess the potential impact on criminal justice involvement, employment, health, and housing outcomes for individuals at high risk of entanglement with the justice system.
Experts believe that GLP-1 drugs offer a promising new avenue for treating addiction, particularly for substances like cocaine, for which medication options are limited. The medications' long-acting nature, requiring only a weekly injection, is seen as an advantage over daily regimens for other addiction treatments. Additionally, GLP-1s are not considered to have abuse potential and can be administered without direct medical supervision.
Beyond addiction, the trial will explore broader societal impacts. The researchers hope to ascertain if these drugs can reduce crime, homelessness, and instances of child abuse and neglect by stabilizing individuals and improving their overall well-being.
CASPR previously conducted a pilot program in Providence, Rhode Island, with these medications, reporting significant success. One participant, Jessica Massarone, who had a history of cocaine and opioid use and whose children were in foster care, reported that the GLP-1 medication helped her manage cravings and triggers. After nearly two years of sobriety, she is working to rebuild relationships with her children.
Nicholas Reville, cofounder of CASPR, noted that GLP-1s can help "quiet the noise" of cravings for various substances, potentially restoring personal agency. He believes that when individuals feel more in control, they are better equipped to make positive decisions for themselves and their families.
The drugs' side effects, such as weight loss, improved diabetes management, and reduced inflammation, are considered largely beneficial. The article suggests that current approaches to addiction treatment, which often rely on short-term rehabilitation and harm reduction models, may be insufficient for chronic addiction, especially when it intersects with the criminal justice or child welfare systems.
The trial seeks to explore whether addressing the physiological aspect of cravings through GLP-1s can make individuals more receptive to existing interventions and incentives aimed at recovery and rehabilitation.